Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Liver Diseases

  Free Subscription


Articles published in Clin Res Hepatol Gastroenterol

Retrieve available abstracts of 183 articles:
HTML format



Single Articles


    May 2022
  1. MOREIRA-SILVA H, Amorim J, Santos-Silva E
    Incidental Liver Lesions in children: A practical and evidence-based approach.
    Clin Res Hepatol Gastroenterol. 2022;46:101904.
    PubMed     Abstract available


  2. ELGENIDY A, Afifi AM, Awad AK, Jalal PK, et al
    Utility of serum angiopoietin-2 as diagnostic marker of hepatocellular carcinoma: A systematic review and diagnostic test accuracy meta-analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101909.
    PubMed    


  3. SHI Q, Liu J, Li T, Zhou C, et al
    Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101893.
    PubMed     Abstract available


  4. BOULOUTA A, Aggeletopoulou I, Kanaloupitis S, Tsounis EP, et al
    The impact of metabolic health on non-alcoholic fatty liver disease (NAFLD). A single center experience.
    Clin Res Hepatol Gastroenterol. 2022;46:101896.
    PubMed     Abstract available


  5. TRIPON S, Bilbault P, Fabacher T, Lefebvre N, et al
    Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with COVID-19.
    Clin Res Hepatol Gastroenterol. 2022;46:101894.
    PubMed     Abstract available


  6. YOU Y, Hu S
    Aberrant expression of the esophageal carcinoma related gene 4 as a prognostic signature for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101891.
    PubMed     Abstract available


  7. ZHAO Y, Zhang C, Zhang Y, Bo C, et al
    Effects of image-guided adaptive radiotherapy combined with hepatic artery chemoembolization in primary liver cancer patients.
    Clin Res Hepatol Gastroenterol. 2022;46:101889.
    PubMed     Abstract available


    April 2022
  8. SUN L, Deng C, Gu Y, He Y, et al
    Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2022;46:101876.
    PubMed     Abstract available


  9. ZHANG X, Jiang M, Zhang X, Zhang J, et al
    An extracellular matrix-based signature associated with immune microenvironment predicts the prognosis of patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101877.
    PubMed     Abstract available


  10. JAIN A, Kirkpatrick RB, Sobotka LA
    Severe pruritis during pregnancy: More than just intrahepatic cholestasis of pregnancy?
    Clin Res Hepatol Gastroenterol. 2022;46:101875.
    PubMed    


  11. LI L, Xin Y, Zhang X, Chen Y, et al
    The effectiveness of radiofrequency ablation for patients with BCLC B1 stage hepatocellular carcinoma downgraded by transarterial chemoembolization.
    Clin Res Hepatol Gastroenterol. 2022;46:101878.
    PubMed     Abstract available


  12. HOORNAERT E, Yombi JC, Coubeau L, Baldin P, et al
    Liver hypodense infectious lesions: Is it only bacteria, parasites or fungi?
    Clin Res Hepatol Gastroenterol. 2022;46:101872.
    PubMed    


  13. WASUWANICH P, So JM, Scheimann AO, Spahic H, et al
    Hepatic and non-hepatic hydrothorax in pediatric ascites.
    Clin Res Hepatol Gastroenterol. 2022;46:101868.
    PubMed     Abstract available


  14. ARTRU F, Moschouri E, Denys A
    Direct intrahepatic portocaval shunt (DIPS) or transjugular transcaval intrahepatic portosystemic shunt (TTIPS) to treat complications of portal hypertension: Indications, technique, and outcomes beyond Budd-Chiari syndrome.
    Clin Res Hepatol Gastroenterol. 2022;46:101858.
    PubMed     Abstract available


  15. WANG H, He X, Fang D, Wang X, et al
    Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
    Clin Res Hepatol Gastroenterol. 2022;46:101853.
    PubMed     Abstract available


  16. ZHANG S, Zhao Y, He L, Bo C, et al
    Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101851.
    PubMed     Abstract available


  17. CANIVET CM, Smati S, Lannes A, Brisseau J, et al
    Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners.
    Clin Res Hepatol Gastroenterol. 2022;46:101848.
    PubMed     Abstract available


  18. ZHU X, Lin X, Zhang P, Liu Y, et al
    Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: A case-control and an intervention study.
    Clin Res Hepatol Gastroenterol. 2022;46:101843.
    PubMed     Abstract available


  19. ATHYROS VG, Katsiki N, Mikhailidis DP
    Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101842.
    PubMed    


  20. ZHANG C, Zhang B, Chen A, Yin Q, et al
    Trans-anethole attenuates diet-induced nonalcoholic steatohepatitis through suppressing TGF-beta-mediated fibrosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101833.
    PubMed     Abstract available


  21. SHAHID A, Cheema HA
    Can statins finally provide the breakthrough in the treatment of non-alcoholic fatty liver disease?
    Clin Res Hepatol Gastroenterol. 2022;46:101826.
    PubMed    


  22. LYU T, Yao H, Wang J, Song L, et al
    Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus.
    Clin Res Hepatol Gastroenterol. 2022;46:101819.
    PubMed     Abstract available


  23. FATIMA K, Moeed A, Waqar E, Atif AR, et al
    Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101816.
    PubMed     Abstract available


  24. LONCAR Y, Tartrat N, Lastennet D, Lemoine L, et al
    Pulmonary infection after hepatic resection: Associated factors and impact on outcomes.
    Clin Res Hepatol Gastroenterol. 2022;46:101733.
    PubMed     Abstract available


    March 2022
  25. CORDEIRO A, Ribamar A, Ramalho A
    Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19.
    Clin Res Hepatol Gastroenterol. 2022;46:101807.
    PubMed     Abstract available


  26. JU S, Wang W, Chen P, Li F, et al
    Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
    Clin Res Hepatol Gastroenterol. 2022;46:101859.
    PubMed     Abstract available


  27. DUMORTIER J, Simon M, Bouhour F
    Fatal myositis and myasthenia induced by atezolizumab for the treatment of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2022;46:101854.
    PubMed    


  28. DANA J, Girard M, Franchi-Abella S, Berteloot L, et al
    Comparison of Transient Elastography, ShearWave Elastography, Magnetic Resonance Elastography and FibroTest as routine diagnostic markers for assessing liver fibrosis in children with Cystic Fibrosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101855.
    PubMed     Abstract available


  29. LI J, Huang WF, Zhang JY
    A rare case of duodenal neuroendocrine tumor with hepatic metastasis.
    Clin Res Hepatol Gastroenterol. 2022;46:101850.
    PubMed    


  30. TANG J, Chen C, Zhou M, Wang J, et al
    NLR contributed to the diagnosis and detection of nonalcoholic fatty liver disease: A meta - analysis.
    Clin Res Hepatol Gastroenterol. 2022;46:101847.
    PubMed    


  31. VALTIS YK, Barlowe T, Young JH, Lichtman AH, et al
    A woman presenting with an unusual cause of fulminant liver failure and sepsis.
    Clin Res Hepatol Gastroenterol. 2022;46:101836.
    PubMed     Abstract available


  32. WU D, Zhang R, Zhan L
    Transglutaminase 3 expression in hepatocellular carcinoma patients: Correlation with tumor features and survival profile.
    Clin Res Hepatol Gastroenterol. 2022;46:101812.
    PubMed     Abstract available


  33. TANG J, Huang Z, Xu J, Lv Q, et al
    Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
    Clin Res Hepatol Gastroenterol. 2022;46:101814.
    PubMed     Abstract available


  34. SCHAEFER A, Journaux M, Mourabit HE, Mouri S, et al
    A systemic mechanism of increased transendothelial migration of leukocytes through the blood-brain barrier in hepatic encephalopathy.
    Clin Res Hepatol Gastroenterol. 2022;46:101801.
    PubMed     Abstract available


  35. BATOOL SS, Dauer M, Weber SN, Liebe R, et al
    Intrahepatic cholestasis of pregnancy in conjunction with a frameshift deletion in FGFR4.
    Clin Res Hepatol Gastroenterol. 2022;46:101800.
    PubMed     Abstract available


  36. CAI Y, Wu D, Zhan L
    CCT6A expression in hepatocellular carcinoma and its correlation with clinical characteristics, liver function indexes, tumor markers and prognosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101796.
    PubMed     Abstract available


  37. PAPAEFTHYMIOU A, Koffas A, Laskaratos FM, Epstein O, et al
    Upper gastrointestinal video capsule endoscopy: The state of the art.
    Clin Res Hepatol Gastroenterol. 2022;46:101798.
    PubMed     Abstract available


    February 2022
  38. THOMAS LS, Geoffroy V, Patrick C, Rodolphe A, et al
    Infectious complications of portal biliopathy leading to liver transplantation.
    Clin Res Hepatol Gastroenterol. 2022 Feb 10:101879.
    PubMed    


  39. KAPS L, Hildebrand K, Nagel M, Michel M, et al
    Validation of EncephalApp_Stroop as screening tool for the detection of minimal hepatic encephalopathy in German patients with liver cirrhosis.
    Clin Res Hepatol Gastroenterol. 2022 Feb 3:101873.
    PubMed     Abstract available


  40. DU M, Yang S, Liu M, Liu J, et al
    COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms.
    Clin Res Hepatol Gastroenterol. 2022;46:101793.
    PubMed     Abstract available


  41. MACEDO MB, Giardini HAM, Pereira RMR
    A retracted diagnosis-when liver capsule retraction is not what it seems.
    Clin Res Hepatol Gastroenterol. 2022;46:101823.
    PubMed    


  42. VITELLIUS C, Paisant A, Lannes A, Chaigneau J, et al
    Liver fibrosis staging by computed tomography: Prospective randomized multicentric evaluation of image analyses.
    Clin Res Hepatol Gastroenterol. 2022;46:101797.
    PubMed     Abstract available


  43. HE S, Chen W, Yang Y, Tang X, et al
    Adult diffuse hepatic hemangiomatosis: A case report and review of the literature.
    Clin Res Hepatol Gastroenterol. 2022;46:101789.
    PubMed     Abstract available


  44. WANG L, Peng Y, Qian Y, Liu Z, et al
    Transjugular extrahepatic portosystemic shunt (TEPS) creation in patients with complete occlusion of portal vein: Primary experience in a single medical center.
    Clin Res Hepatol Gastroenterol. 2022;46:101786.
    PubMed    


  45. CAMPION B, Larrey E, Wagner M, Rudler M, et al
    Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage a trois" !
    Clin Res Hepatol Gastroenterol. 2022;46:101785.
    PubMed    


  46. HUANG L, Liu J, Bie C, Liu H, et al
    Advances in cell death - related signaling pathways in acute-on-chronic liver failure.
    Clin Res Hepatol Gastroenterol. 2022;46:101783.
    PubMed     Abstract available


  47. LI Q, Xu H, Sui C, Zhang H, et al
    Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus.
    Clin Res Hepatol Gastroenterol. 2022;46:101781.
    PubMed     Abstract available


    January 2022
  48. XIN H, Zhang C, Ding Z, Zhang M, et al
    TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports.
    Clin Res Hepatol Gastroenterol. 2022;46:101777.
    PubMed    


  49. NAULT JC, Blanc JF, Moga L, Calderaro J, et al
    Non-invasive diagnosis and follow-up of benign liver tumours.
    Clin Res Hepatol Gastroenterol. 2022;46:101765.
    PubMed     Abstract available


  50. DE LEDINGHEN V
    Non-invasive diagnosis and follow-up of chronic liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101763.
    PubMed    


  51. NAHON P, Aube C, Moga L, Chalaye J, et al
    Non-invasive diagnosis and follow-up of primary malignant liver tumours.
    Clin Res Hepatol Gastroenterol. 2022;46:101766.
    PubMed     Abstract available


  52. CORPECHOT C, Heurgue A, Tanne F, Potier P, et al
    Non-invasive diagnosis and follow-up of primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2022;46:101770.
    PubMed     Abstract available


  53. BOURSIER J, Guillaume M, Bouzbib C, Lannes A, et al
    Non-invasive diagnosis and follow-up of non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101769.
    PubMed     Abstract available


  54. RAUTOU PE, Elkrief L, Decraecker M, Ollivier-Hourmand I, et al
    Non-invasive diagnosis and follow-up of vascular liver diseases.
    Clin Res Hepatol Gastroenterol. 2022;46:101764.
    PubMed     Abstract available


  55. SOBESKY R, Guillaud O, Bouzbib C, Sogni P, et al
    Non-invasive diagnosis and follow-up of rare genetic liver diseases.
    Clin Res Hepatol Gastroenterol. 2022;46:101768.
    PubMed     Abstract available


  56. BOURSIER J, Decraecker M, Bourliere M, Bureau C, et al
    Quality criteria for the measurement of liver stiffness.
    Clin Res Hepatol Gastroenterol. 2022;46:101761.
    PubMed     Abstract available


  57. CHEN BR, Pan CQ
    Non-invasive assessment of fibrosis and steatosis in pediatric non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2022;46:101755.
    PubMed     Abstract available


  58. STEMPAK-DROISSART T, Rousset-Jablonski C, Spritzer PM, Lalhou N, et al
    Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women.
    Clin Res Hepatol Gastroenterol. 2022;46:101756.
    PubMed     Abstract available


  59. HOUNTONDJI L, Debourdeau A, Meunier L
    Acute liver failure secondary to Langerhans cell histiocytosis.
    Clin Res Hepatol Gastroenterol. 2022;46:101744.
    PubMed    


  60. ZIMMER V, Emrich K
    Nodular gastric antral vascular ectasia: Distinct portal hypertensive hyperplastic polyp lesions.
    Clin Res Hepatol Gastroenterol. 2022;46:101745.
    PubMed    


  61. DU J, Zhang J, Chen X, Zhang S, et al
    Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients.
    Clin Res Hepatol Gastroenterol. 2022;46:101697.
    PubMed     Abstract available


    December 2021
  62. BORIE F, Dubray V, Tretarre B
    Impact of recommendations and new therapies on the prognosis of colon cancer with synchronous liver metastasis.
    Clin Res Hepatol Gastroenterol. 2021 Dec 25:101856.
    PubMed     Abstract available


    November 2021
  63. SOBOTKA LA, Mumtaz K, Hinton A, Conteh LF, et al
    The Time to Advocate for Influenza Vaccines in Patients with Cirrhosis is Now.
    Clin Res Hepatol Gastroenterol. 2021 Nov 20:101838.
    PubMed     Abstract available


  64. MOREIRA JLS, Barbosa SMB, Goncalves Junior J
    Pathophysiology and molecular mechanisms of liver injury in severe forms of COVID-19: An integrative review.
    Clin Res Hepatol Gastroenterol. 2021;45:101752.
    PubMed     Abstract available


  65. THOEN RU, Longo L, Neto SC, Alvares-da-Silva MR, et al
    Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2021;45:101638.
    PubMed     Abstract available


  66. RUTHER DF, Sebode M, Lohse AW, Wernicke S, et al
    Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER.
    Clin Res Hepatol Gastroenterol. 2021;45:101760.
    PubMed     Abstract available


  67. TUTUNCHI H, Naeini F, Ebrahimi-Mameghani M, Najafipour F, et al
    Metabolically healthy and unhealthy obesity and the progression of liver fibrosis: A cross-sectional study.
    Clin Res Hepatol Gastroenterol. 2021;45:101754.
    PubMed     Abstract available


  68. ZHAO J, Wang Y, Su H, Su L, et al
    Non-coding RNAs as biomarkers for hepatocellular carcinoma-A systematic review.
    Clin Res Hepatol Gastroenterol. 2021;45:101736.
    PubMed     Abstract available


  69. BLAISE L, Pereira H, Vilgrain V, Sutter O, et al
    Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion.
    Clin Res Hepatol Gastroenterol. 2021;45:101731.
    PubMed     Abstract available


  70. WONG YJ, Kew GS, Tan PS, Chen Z, et al
    Novel albumin, bilirubin and platelet criteria for the exclusion of high-risk varices in compensated advanced chronic liver disease: A validation study.
    Clin Res Hepatol Gastroenterol. 2021;45:101598.
    PubMed     Abstract available


  71. MOTAMED N, Nikkhah M, Karbalaie Niya MH, Khoonsari M, et al
    The Ability of the Framingham Steatosis Index (FSI) to Predict Non-alcoholic Fatty Liver Disease (NAFLD): A Cohort Study.
    Clin Res Hepatol Gastroenterol. 2021;45:101567.
    PubMed     Abstract available


  72. BOUZBIB C, Cluzel P, Sultanik P, Bernard-Chabert B, et al
    Prognosis of patients undergoing salvage TIPS is still poor in the preemptive TIPS era.
    Clin Res Hepatol Gastroenterol. 2021;45:101593.
    PubMed     Abstract available


  73. HOU H, Chen D, Liu J, Feng L, et al
    Zinc monotherapy for young patients with oligosymptomatic Wilson disease: A single center, retrospective study.
    Clin Res Hepatol Gastroenterol. 2021;45:101623.
    PubMed     Abstract available


  74. GE J, Zhang X, Zhang B, Zhu L, et al
    Higher tumor protein kinase D1 correlates with increased tumor size, BCLC stage, CA199 level, AFP level and worse overall survival in hepatocellular carcinoma patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101573.
    PubMed     Abstract available


  75. LI X, Yu Y, Liu L
    Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101545.
    PubMed     Abstract available


  76. VEYRE F, Dumortier J, Radenne S, Valette PJ, et al
    Rare isolated spontaneous hepatic artery thrombosis in a non-transplant patient.
    Clin Res Hepatol Gastroenterol. 2021;45:101453.
    PubMed    


  77. VANDE BERG P, Borbath I, Baldin P, Vande Berg D, et al
    Granuloma formation within perihepatic lymphadenopathy.
    Clin Res Hepatol Gastroenterol. 2021;45:101504.
    PubMed    


  78. ABDI SAH, Shukla S, Khan J, Al Zahrani A, et al
    Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101443.
    PubMed    


    October 2021
  79. ZHANG L, Zhou Y, Zhang J
    An incidental hepatic lesion in a cirrhotic liver.
    Clin Res Hepatol Gastroenterol. 2021 Oct 28:101825.
    PubMed    


  80. MOGA L, Robic MA, Blasco-Perrin H, Cabarrou P, et al
    Acute kidney injury in patients with cirrhosis: prospective longitudinal study in 405 patients.
    Clin Res Hepatol Gastroenterol. 2021 Oct 27:101822.
    PubMed     Abstract available


    September 2021
  81. CHAIBI S, Boussier J, Hajj WE, Abitbol Y, et al
    Liver function test abnormalities are associated with a poorer prognosis in Covid-19 patients: Results of a French cohort.
    Clin Res Hepatol Gastroenterol. 2021;45:101556.
    PubMed     Abstract available


  82. MALEZIEUX E, Meunier L, Riviere B, Larrey D, et al
    Hydrochlorothiazide-induced hepatotoxicity: A rare case of DILI.
    Clin Res Hepatol Gastroenterol. 2021;45:101599.
    PubMed     Abstract available


  83. CHEN S, Zhao E
    Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101587.
    PubMed     Abstract available


  84. BAUMANN U, Sturm E, Lacaille F, Gonzales E, et al
    Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
    Clin Res Hepatol Gastroenterol. 2021;45:101751.
    PubMed     Abstract available


  85. WAHLIN S, Andersson J
    Liver health literacy and social stigma of liver disease: A general population e-survey.
    Clin Res Hepatol Gastroenterol. 2021;45:101750.
    PubMed     Abstract available


  86. LI X, Yao Q, Li R, Jin Y, et al
    Isoflurane induces liver injury by modulating the expression of miR-125a-5p.
    Clin Res Hepatol Gastroenterol. 2021;45:101732.
    PubMed     Abstract available


  87. BENARD J, Lafrance MJ, Gordien E, Amaral L, et al
    Hepatitis B virus-associated hepatocellular carcinoma is still a matter of concern in the French Caribbean Island of Guadeloupe.
    Clin Res Hepatol Gastroenterol. 2021;45:101706.
    PubMed    


  88. YANG M, Wei S, Zhao H, Zhou D, et al
    The role of miRNA125b in the progression of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101712.
    PubMed     Abstract available


  89. LUO L, He X, Li K, Long Y, et al
    Thermal ablation of medium-sized hepatocellular carcinomas using intraoperative ultrasound fusion imaging: A propensity score-matched analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101581.
    PubMed     Abstract available


  90. YANG D, Wu H, Nong W, Zheng M, et al
    A new model based on gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts prognostic outcome after curative resection of solitary hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101509.
    PubMed     Abstract available


  91. DE SOUSA MAGALHAES R, Xavier S, Magalhaes J, Rosa B, et al
    Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101580.
    PubMed     Abstract available


  92. BOEKEN T, Gallois C, Douard R, Meatchi T, et al
    Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor.
    Clin Res Hepatol Gastroenterol. 2021;45:101557.
    PubMed    


    July 2021
  93. DUMORTIER J, Besch C, Moga L, Coilly A, et al
    NON-INVASIVE DIAGNOSIS AND FOLLOW-UP IN LIVER TRANSPLANTATION.
    Clin Res Hepatol Gastroenterol. 2021 Jul 28:101774.
    PubMed     Abstract available


  94. VILLERET F, Dumortier J, Erard-Poinsot D
    How will NAFLD change the liver transplant landscape in the 2020s?
    Clin Res Hepatol Gastroenterol. 2021 Jul 23:101759.
    PubMed     Abstract available


  95. LANTHIER N, Starkel P, Dahlqvist G
    Muscle mass depletion in chronic liver diseases: An accelerated model of aging or a distinct entity?
    Clin Res Hepatol Gastroenterol. 2021;45:101721.
    PubMed     Abstract available


  96. LIU W, Xu C, Meng Q, Kang P, et al
    The clinical value of kinesin superfamily protein 2A in hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101527.
    PubMed     Abstract available


  97. CAMPOS-MURGUIA A, Valdez-Hernandez P, Cordova-Gallardo J, Arteaga-Vazquez J, et al
    Prevalence and clinical characteristics of alpha-1 antitrypsin deficiency in liver explants in a Mexican cohort.
    Clin Res Hepatol Gastroenterol. 2021;45:101519.
    PubMed     Abstract available


  98. KIM KM, Roh JH, Lee S, Yoon JH, et al
    Do renin-angiotensin system inhibitors reduce risk for hepatocellular carcinoma?: A nationwide nested case-control study.
    Clin Res Hepatol Gastroenterol. 2021;45:101510.
    PubMed     Abstract available


  99. CAI L, Li H, Guo J, Zhao W, et al
    Drug-eluting bead transarterial chemoembolization is an effective downstaging option for subsequent radical treatments in patients with hepatocellular carcinoma: A cohort study.
    Clin Res Hepatol Gastroenterol. 2021;45:101535.
    PubMed     Abstract available


  100. SHI JY, Sun LY, Quan B, Xing H, et al
    A novel online calculator based on noninvasive markers (ALBI and APRI) for predicting post-hepatectomy liver failure in patients with hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2021;45:101534.
    PubMed     Abstract available


  101. IM HJ, Ahn YC, Wang JH, Lee MM, et al
    Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea.
    Clin Res Hepatol Gastroenterol. 2021;45:101526.
    PubMed     Abstract available


  102. PERRAULT F, Echelard P, Viens D, Borduas M, et al
    Contraceptive vaginal ring-induced cholestasis in a patient with a history of intrahepatic cholestasis of pregnancy.
    Clin Res Hepatol Gastroenterol. 2021;45:101475.
    PubMed     Abstract available


  103. LIU J, Dai XL, Zhou XJ, Gu BH, et al
    Metamizole-induced acute liver failure in a boy.
    Clin Res Hepatol Gastroenterol. 2021;45:101570.
    PubMed    


  104. MOSCHOURI E, Hocquelet A, Vermersch M, Fraga M, et al
    DIPS, a safe and effective alternative in patients with unfavorable anatomy to TIPSS: first experience in a tertiary center.
    Clin Res Hepatol Gastroenterol. 2021;45:101715.
    PubMed    


  105. COLAK Y, Hasan B, Erkalma B, Tandon K, et al
    Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target.
    Clin Res Hepatol Gastroenterol. 2021;45:101710.
    PubMed     Abstract available


  106. ILUZ-FREUNDLICH D, Grubert Van Iderstine M, Uhanova J, Zhang M, et al
    Low serum alkaline phosphatase levels in patients with chronic liver diseases: Possible contributions to disease pathogenesis.
    Clin Res Hepatol Gastroenterol. 2021;45:101694.
    PubMed     Abstract available


    June 2021
  107. QU Y, Li T, Lin C, Liu F, et al
    Animal Naming Test for the Assessment of Minimal Hepatic Encephalopathy in Asian Cirrhotic Populations.
    Clin Res Hepatol Gastroenterol. 2021 Jun 3:101729.
    PubMed     Abstract available


  108. RAZAQ S, Kara M, Ozcakar L
    Measure Grip Strength, Gait Speed and Quadriceps Muscle in Cirrhosis. Comment to "Frailty, sarcopenia and mortality in cirrhosis: What is the best assessment, how to interpret the data correctly and what interventions are possible?"
    Clin Res Hepatol Gastroenterol. 2021 Jun 1:101727.
    PubMed    


    May 2021
  109. VUJAKLIJA BRAJKOVIC A, Zlopasa O, Gubarev Vrdoljak N, Goran T, et al
    Acute liver and cardiac failure in multisystem inflammatory syndrome in adults after COVID-19.
    Clin Res Hepatol Gastroenterol. 2021;45:101678.
    PubMed    


  110. SERRA F, Bonaduce I, De Ruvo N, Cautero N, et al
    Covid-19 and hepatic injury: A systematic review.
    Clin Res Hepatol Gastroenterol. 2021;45:101605.
    PubMed    


  111. SHIHA G, Soliman R, Mikhail N, Zaky S, et al
    HCC developed in CHC patients who achieved SVR following DAAs tend to display less aggressive pattern.
    Clin Res Hepatol Gastroenterol. 2021;45:101608.
    PubMed    


  112. WORLAND T, O'Neill P, Rusli F
    Resolution of metastatic hepatocellular carcinoma with sour cherry intake.
    Clin Res Hepatol Gastroenterol. 2021;45:101663.
    PubMed    


  113. DEVICTOR J, Leclercq A, Hazo JB, Burnet E, et al
    Nurse coordinator roles in the management of patients with hepatocellular carcinoma: A French national survey.
    Clin Res Hepatol Gastroenterol. 2021;45:101650.
    PubMed     Abstract available


  114. MU X, Tong J, Xu X, Chen J, et al
    World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure.
    Clin Res Hepatol Gastroenterol. 2021;45:101548.
    PubMed     Abstract available


  115. ARAZ M, Kilinc F, Kerimoglu U, Keskin M, et al
    Irinotecan-induced NASH and liver failure.
    Clin Res Hepatol Gastroenterol. 2021;45:101606.
    PubMed    


  116. KALOGIROU MS, Patoulias D, Haidich AB, Akriviadis E, et al
    Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2021;45:101568.
    PubMed     Abstract available


  117. LIN M, Zeng H, Deng G, Lei J, et al
    Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101530.
    PubMed     Abstract available


  118. KARNSAKUL W, Wasuwanich P, Ingviya T, Laengvejkal P, et al
    Clinical usage of serum albumin to ascitic fluid albumin gradient and ascitic fluid total protein in pediatric ascites.
    Clin Res Hepatol Gastroenterol. 2021;45:101549.
    PubMed     Abstract available


  119. KARATAS E, Bouchecareilh M
    Alpha 1-Antitrypsin deficiency in liver explants in a Mexican cohort: A unique cohort to assess the role of heterozygous genotypes in liver disease.
    Clin Res Hepatol Gastroenterol. 2021;45:101538.
    PubMed    


  120. DE MUNCK TJI, Verhaegh P, Lodewick T, Bakers F, et al
    Myosteatosis in nonalcoholic fatty liver disease: An exploratory study.
    Clin Res Hepatol Gastroenterol. 2021;45:101500.
    PubMed     Abstract available


  121. DE VOS N, Van der Meulen J, Van Der Linden M, Claes K, et al
    Myxoid hepatocellular adenoma, a rare variant of hepatocellular adenoma with distinct imaging features: A case report with immunohistochemical and molecular analysis and literature review.
    Clin Res Hepatol Gastroenterol. 2021;45:101478.
    PubMed     Abstract available


  122. LYKAVIERIS P, Bernard O, Jacquemin E
    Ursodeoxycholic acid therapy throughout pregnancy in women affected with chronic cholestasis of childhood: No evidence for teratogenicity.
    Clin Res Hepatol Gastroenterol. 2021;45:101472.
    PubMed    


  123. RIVAS M, Aguiar T, Fernandes G, Lemes R, et al
    DNA methylation as a key epigenetic player for hepatoblastoma characterization.
    Clin Res Hepatol Gastroenterol. 2021;45:101684.
    PubMed     Abstract available


  124. BOILLOT O, Cayot B, Guillaud O, Crozet-Chaussin J, et al
    Partial major hepatectomy with cyst fenestration for polycystic liver disease: Indications, short and long-term outcomes.
    Clin Res Hepatol Gastroenterol. 2021;45:101670.
    PubMed     Abstract available


  125. KULKARNI AV, Tevethia HV, Arab JP, Candia R, et al
    Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101675.
    PubMed     Abstract available


  126. ZAREBSKA I, Gzil A, Durslewicz J, Jaworski D, et al
    The clinical, prognostic and therapeutic significance of liver cancer stem cells and their markers.
    Clin Res Hepatol Gastroenterol. 2021;45:101664.
    PubMed     Abstract available


    April 2021
  127. OZCELIK F
    Prognostic value of gamma-glutamyl transpeptidase in liver cirrhosis and hepatocellular cancer regardless of other parameters.
    Clin Res Hepatol Gastroenterol. 2021 Apr 27:101708.
    PubMed    


  128. CARDOSO CC, Matiollo C, Pereira CHJ, Fonseca JS, et al
    B-cell compartment abnormalities are associated with ACLF and mortality in patients with liver cirrhosis.
    Clin Res Hepatol Gastroenterol. 2021 Apr 11:101698.
    PubMed     Abstract available


    March 2021
  129. TORNAI D, Vitalis Z, Jonas A, Janka T, et al
    Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality.
    Clin Res Hepatol Gastroenterol. 2021;45:101579.
    PubMed     Abstract available


  130. CAO X, Cao Z, Ou C, Zhang L, et al
    Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101583.
    PubMed     Abstract available


  131. CORPECHOT C
    The revival of preemptive UDCA therapy in liver transplant recipients: Commentary to "UDCA decreases Incidence of Primary Biliary Cholangitis and Biliary Complications after Liver Transplant: A Meta-Analysis" by Pedersen et al., Liver Transplant, Nove
    Clin Res Hepatol Gastroenterol. 2021 Mar 13:101679.
    PubMed    


  132. ALTIERI M, Seree O, Lobbedez T, Segol P, et al
    Risk factors of de novo malignancies after liver transplantation: a French national study on 11004 adult patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101514.
    PubMed     Abstract available


  133. LANTHIER N, Starkel P, Dahlqvist G
    Frailty, sarcopenia and mortality in cirrhosis: what is the best assessment, how to interpret the data correctly and what interventions are possible?
    Clin Res Hepatol Gastroenterol. 2021 Mar 2:101661.
    PubMed     Abstract available


  134. COUPIER A, Pioche M, Steer N, Zoulim F, et al
    An exceptional case of refractory variceal bleeding occurring during liver transplantation rescued with esophageal stent.
    Clin Res Hepatol Gastroenterol. 2021 Mar 2:101662.
    PubMed    


  135. BLANC JF, Debaillon-Vesque A, Roth G, Barbare JC, et al
    Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI).
    Clin Res Hepatol Gastroenterol. 2021;45:101590.
    PubMed     Abstract available


  136. TIAN J, Hu D
    LncRNA SLC16A1-AS1 is upregulated in hepatocellular carcinoma and predicts poor survival.
    Clin Res Hepatol Gastroenterol. 2021;45:101490.
    PubMed     Abstract available


  137. SOBOTKA LA, Chen JL, Wellner MR
    Compression induced hepatic injury: an unusual case of abnormal liver function tests.
    Clin Res Hepatol Gastroenterol. 2021;45:101655.
    PubMed    


  138. LIU Y, Wu H, Wang Z, Wu J, et al
    Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide.
    Clin Res Hepatol Gastroenterol. 2021;45:101312.
    PubMed     Abstract available


  139. SU Q, Wang H
    Long non-coding RNA 01559 mediates the malignant phenotypes of hepatocellular carcinoma cells through targeting miR-511.
    Clin Res Hepatol Gastroenterol. 2021;45:101648.
    PubMed     Abstract available


  140. ROSSO C, Caviglia GP, Armandi A, Ribaldone DG, et al
    Association between gut permeability and insulin resistance: Any role for zonulin in patients with non-alcoholic fatty liver disease?
    Clin Res Hepatol Gastroenterol. 2021;45:101611.
    PubMed    


  141. XIE Z, Wu Y, Liu S, Lai Y, et al
    LncRNA-SNHG7/miR-29b/DNMT3A axis affects activation, autophagy and proliferation of hepatic stellate cells in liver fibrosis.
    Clin Res Hepatol Gastroenterol. 2021;45:101469.
    PubMed     Abstract available


  142. MAZZOLA A, Magro B, Perdigao F, Charlotte F, et al
    Acute liver failure and HELLP syndrome: A clinical case and literature review.
    Clin Res Hepatol Gastroenterol. 2021;45:101498.
    PubMed     Abstract available


  143. SHEN X, Huang Y, Guo H, Peng H, et al
    Oral ibuprofen promoted cholestatic liver disease in very low birth weight infants with patent ductus arteriosus.
    Clin Res Hepatol Gastroenterol. 2021;45:101495.
    PubMed     Abstract available


  144. XU X, Hou Z, Xu Y, Gu H, et al
    The dynamic of platelet count as a novel and valuable predictor for 90-day survival of hepatitis B virus-related acute-on-chronic liver failure patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101482.
    PubMed     Abstract available


  145. CHEN C, Qiu H, Yao Y, Zhang Z, et al
    Comprehensive predictive factors for CalliSpheres(R) microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101460.
    PubMed     Abstract available


  146. TURPIN A, de Baere T, Heurgue A, Le Malicot K, et al
    Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study.
    Clin Res Hepatol Gastroenterol. 2021;45:101464.
    PubMed     Abstract available


    February 2021
  147. GAO Y, Liu H, Tang F, Zhang X, et al
    Efficacy and safety of anticoagulants in liver cirrhosis patients with portal vein thrombosis: A meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021 Feb 15:101649.
    PubMed     Abstract available


    January 2021
  148. ZHAO N, Liu X, Guo H, Zhao X, et al
    Interleukin-35: An emerging player in the progression of liver diseases.
    Clin Res Hepatol Gastroenterol. 2021;45:101518.
    PubMed     Abstract available


  149. CHARPY F, Debourdeau A, Boivineau L, Meszaros M, et al
    Hepatic amyloidosis as a case of fatal fulminant liver failure.
    Clin Res Hepatol Gastroenterol. 2021;45:101506.
    PubMed    


  150. BRAUNER C, Joveleviths D, Alvares-da-Silva MR
    Hepatotoxicity by methyl methacrylate.
    Clin Res Hepatol Gastroenterol. 2021;45:101513.
    PubMed    


  151. THEVENOT T, Savale L, Sitbon O
    Portopulmonary hypertension: An unfolding story.
    Clin Res Hepatol Gastroenterol. 2021;45:101492.
    PubMed    


  152. WANG J, Feng L, Zhang L
    Combining cellular immunotherapy was an optional choice for unresectable advanced HCC: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2021;45:101440.
    PubMed     Abstract available


  153. LEMAITRE C, Thiebaut PA, Francois A, Michel P, et al
    An unexpected cause of heterogeneous liver.
    Clin Res Hepatol Gastroenterol. 2021;45:101444.
    PubMed    


  154. KANG Y, Park S, Kim S, Han SJ, et al
    Validating the BAVENO VI criteria to identify low risk biliary atresia patients without endoscopy for esophageal varix.
    Clin Res Hepatol Gastroenterol. 2021;45:101437.
    PubMed     Abstract available


  155. RAFFETTI E, Portolani N, Molfino S, Mentasti S, et al
    Is survival for hepatocellular carcinoma increasing? A population-based study on survival of hepatocellular carcinoma patients in the 1990s and 2000s.
    Clin Res Hepatol Gastroenterol. 2021;45:101433.
    PubMed     Abstract available


  156. CHANG Y, He J, Xiang X, Li H, et al
    LUM is the hub gene of advanced fibrosis in nonalcoholic fatty liver disease patients.
    Clin Res Hepatol Gastroenterol. 2021;45:101435.
    PubMed     Abstract available


    November 2020
  157. HUANG C, Seah JJ, Tan CK, Kam JW, et al
    Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Clin Res Hepatol Gastroenterol. 2020 Nov 29:101528.
    PubMed     Abstract available


  158. BEST MG, Wurdinger T
    Tumor-educated platelets for the earlier detection of hepatocellular carcinoma.
    Clin Res Hepatol Gastroenterol. 2020;44:794-795.
    PubMed    


    October 2020
  159. WANG H, Qiu P, Liu J, Wang F, et al
    The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2020;44:653-661.
    PubMed     Abstract available


  160. RAHAL HK, Tabibian JH
    The MBOAT7 rs641738 variant in primary sclerosing cholangitis: A novel biomarker for prognostication.
    Clin Res Hepatol Gastroenterol. 2020;44:619-621.
    PubMed    


    September 2020
  161. ALI N
    Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
    Clin Res Hepatol Gastroenterol. 2020;44:e84-e86.
    PubMed    


    August 2020
  162. ELKRIEF L, Houssel-Debry P, Ackermann O, Franchi-Abella S, et al
    Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction.
    Clin Res Hepatol Gastroenterol. 2020 Aug 17. pii: S2210-7401(20)30091.
    PubMed     Abstract available


    July 2020
  163. TRIPON S, Mayer P, Svab A, Habersetzer F, et al
    Intraabdominal urokinase in the treatment of loculated infected ascites in cirrhosis.
    Clin Res Hepatol Gastroenterol. 2020 Jul 9. pii: S2210-7401(20)30181.
    PubMed     Abstract available


    June 2020
  164. DE GOTTARDI A, Fratila C, Bertoli R, Cerny A, et al
    Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.
    Clin Res Hepatol Gastroenterol. 2020 Jun 10. pii: S2210-7401(20)30159.
    PubMed     Abstract available


  165. GANNE-CARRIE N, Fontaine H, Dumortier J, Boursier J, et al
    Suggestions for the care of patients with liver disease during the Coronavirus 2019 pandemic.
    Clin Res Hepatol Gastroenterol. 2020;44:275-281.
    PubMed     Abstract available


    April 2020
  166. ABERGEL A, Gasperment M, Nery FG, Buchard B, et al
    Extrahepatic portal vein obstruction (EHPVO) in cirrhosis.
    Clin Res Hepatol Gastroenterol. 2020 Apr 17. pii: S2210-7401(20)30089.
    PubMed    


  167. JANKOWSKA I, Czubkowski P, Rokicki D, Lipinski P, et al
    Acute liver failure due to DGUOK deficiency-is liver transplantation justified?
    Clin Res Hepatol Gastroenterol. 2020 Apr 8. pii: S2210-7401(20)30082.
    PubMed     Abstract available


    March 2020
  168. FELLI E, Baumert T, Pessaux P
    Is minimally invasive true anatomical HCC resection a future way to improve results in bridge or salvage liver transplantation?
    Clin Res Hepatol Gastroenterol. 2020 Mar 18. pii: S2210-7401(20)30049.
    PubMed    


  169. MORANDEAU E, Rayer C, Jezequel C, Guyader D, et al
    Hepatic encephalopathy post liver transplantation.
    Clin Res Hepatol Gastroenterol. 2020 Mar 10. pii: S2210-7401(20)30039.
    PubMed    


    January 2020
  170. PETA V, Zhu J, Lubman DM, Huguet S, et al
    Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
    Clin Res Hepatol Gastroenterol. 2020 Jan 18. pii: S2210-7401(19)30272.
    PubMed     Abstract available


  171. HEDJOUDJE A, Cervoni JP, Patry C, Chatot M, et al
    Takotsubo cardiomyopathy triggered by delirium tremens in a cirrhotic patient with acute-on-chronic liver failure: A case report.
    Clin Res Hepatol Gastroenterol. 2020 Jan 9. pii: S2210-7401(19)30262.
    PubMed     Abstract available


    December 2019
  172. GOUMARD C, Scatton O
    Resectable HCC: Should salvage liver transplantation for HCC be discussed de principe?
    Clin Res Hepatol Gastroenterol. 2019 Dec 18. pii: S2210-7401(19)30251.
    PubMed    


    November 2019
  173. ALLAIRE M, Cadranel JF, Nguyen TTN, Garioud A, et al
    Management of infections in patients with cirrhosis in the context of increasing therapeutic resistance: A systematic review.
    Clin Res Hepatol Gastroenterol. 2019 Nov 6. pii: S2210-7401(19)30224.
    PubMed     Abstract available


    October 2019
  174. ALLAIRE M, Walter A, Sutter O, Nahon P, et al
    TIPS for management of portal-hypertension-related complications in patients with cirrhosis.
    Clin Res Hepatol Gastroenterol. 2019 Oct 26. pii: S2210-7401(19)30217.
    PubMed     Abstract available


    August 2019
  175. WANLESS IR
    Quantitative SHG-microscopy: Unraveling the nano-architecture of the cirrhotic liver.
    Clin Res Hepatol Gastroenterol. 2019 Aug 12. pii: S2210-7401(19)30174.
    PubMed    


    June 2019
  176. LIBERAL R, Gaspar R, Lopes S, Macedo G, et al
    Primary biliary cholangitis in patients with inflammatory bowel disease.
    Clin Res Hepatol Gastroenterol. 2019 Jun 3. pii: S2210-7401(19)30099.
    PubMed     Abstract available


    April 2019
  177. SCHIELKE A, Scatton O, Boelle PY, Perdigao F, et al
    Ischemic-type biliary lesions: A leading indication of liver retransplantation with excellent results.
    Clin Res Hepatol Gastroenterol. 2019;43:131-139.
    PubMed     Abstract available


  178. MURATORI P, Lenzi M, Muratori L
    Diagnosis of primary biliary cholangitis in a "teen" male patient.
    Clin Res Hepatol Gastroenterol. 2019;43:e20-e21.
    PubMed    


    March 2019
  179. YANG F, Ren H, Gao Y, Zhu Y, et al
    The value of severe vitamin D deficiency in predicting the mortality risk of patients with liver cirrhosis: A meta-analysis.
    Clin Res Hepatol Gastroenterol. 2019 Mar 29. pii: S2210-7401(19)30052.
    PubMed     Abstract available


  180. MAESTAS C, Lazkani M, Sultan M, Kolli G, et al
    Severe takotsubo cardiomyopathy following orthotopic liver transplantation: A case series.
    Clin Res Hepatol Gastroenterol. 2019 Mar 7. pii: S2210-7401(18)30266.
    PubMed     Abstract available


  181. QU W, Zhu ZJ, Wei L, Sun LY, et al
    Feasibility of domino liver transplantation from hyperhomocsyteinemia.
    Clin Res Hepatol Gastroenterol. 2019 Mar 7. pii: S2210-7401(19)30039.
    PubMed     Abstract available


    January 2019
  182. LEBRAY P, Varnous S
    Combined heart and liver transplantation: State of knowledge and outlooks.
    Clin Res Hepatol Gastroenterol. 2019 Jan 8. pii: S2210-7401(18)30173.
    PubMed     Abstract available


    December 2018
  183. BERGERE M, Erard-Poinsot D, Boillot O, Valette PJ, et al
    Portal vein thrombosis and liver cirrhosis: Long-term anticoagulation is effective and safe.
    Clin Res Hepatol Gastroenterol. 2018 Dec 18. pii: S2210-7401(18)30268.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: